Bolt Biotherapeutics, Inc. (BOLT)

Market Cap	39.47M
Revenue (ttm)	6.78M
Net Income (ttm)	-76.79M
Shares Out	37.95M
EPS (ttm)	-2.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	280,628
Open	1.10
Previous Close	1.09
Day's Range	1.02 - 1.12
52-Week Range	1.01 - 2.03
Beta	0.86
Analysts	Buy
Price Target	5.00 (+380.77%)
Earnings Date	Nov 9, 2023

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 94
• Stock Exchange: NASDAQ
• Ticker Symbol: BOLT

Financial Performance

In 2022, BOLT's revenue was $5.73 million, an increase of 354.68% compared to the previous year's $1.26 million. Losses were -$88.10 million, -10.64% less than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for BOLT stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 380.77% from the latest price.

Price Target

$5.0

(380.77% upside)

Analyst Consensus: Buy